🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Singapore / NCT07438353
Starting soon Not applicable

Home-Based Digital Rehabilitation Program Optimized With Transcutaneous Spinal Cord Stimulation for Upper Limb Functional Enhancement in Tetraplegia (HOPE): A Safety, Efficacy, and Feasibility Study

NCT07438353 · tracked via the Priya Life Science Singapore tracker
Phase
Not applicable
Started
2026-04
Last updated
2026-02-27

Condition(s) studied

Spinal Cord InjuryQuadriplegia/Tetraplegia

Investigational drug(s) / intervention(s)

Home-based digital rehabilitation programme with tSCS

Home-based digital rehabilitation programme with tSCS: Home-based digital rehabilitation programme with tSCS introduced at staggered time points following varying duration of baseline usual care

Study summary

Individuals with chronic cervical spinal cord injury (SCI) and tetraplegia commonly experience persistent impairment in upper limb function, leading to reduced independence and quality of life. Transcutaneous spinal cord stimulation (tSCS) is a non-invasive neuromodulation technique that has demonstrated potential to improve upper limb strength and function when combined with rehabilitation. However, access to tSCS is limited in Singapore due to cost, regulatory barriers, and the need for frequent outpatient therapy.

This study evaluates the safety, efficacy, and feasibility of a home-based digital rehabilitation program incorporating tSCS delivered using a commercially available neuromuscular electrical stimulation (NMES) device. Using a prospective, open-label single-case experimental design with multiple baselines across participants, individuals with chronic, non-progressive cervical SCI will receive daily home-based tSCS combined with an mobile application-guided upper limb exercise program. Upper limb function, quality of life, feasibility, and safety outcomes will be assessed longitudinally over a 22-week study period.

Eligibility

Sex
ALL
Min age
21 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: Participant * Age 21 -75 years; * Non-progressive cervical SCI/spinal cord dysfunction (traumatic or non-traumatic); * Duration of SCI/spinal cord dysfunction more than or equal to 12 months; * ASIA Impairment scale (AIS B, C, or D) with impaired upper limb function; * At least one hand capable of grasp and pinch, with or without assistive modification; * International Standards for Neurological Classification of Spinal Cord Injury-Upper Extremity Measurement Scale (ISNCSCI-UEMS) more than or equal to 20; * Able to maintain an upright sitting position for at least 30 minutes; * No contraindication for tSCS (e.g., no pacemakers or other implantable stimulators); * Motivated and able to engage in a daily home-based rehabilitation program; * Availability of a dedicated care-giver to set up digital home-based therapy program Caregiver * Age 21 -75 years; * As identified by the patient as the caregiver; * Willing to participate in the study Exclusion Criteria: Participant * Significant or unstable medical co-morbidities including uncontrolled cardiopulmonary disease, severe cognitive impairment, severe dysautonomia, as determined by the investigator; * Pregnancy; * History of other neurologic conditions affecting upper limb function, such as stroke, multiple sclerosis, or traumatic brain injury; * Known history of peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc); * Ongoing treatment for cancer; * Skin conditions or active cancerous lesion that limit the application of tSCS electrodes * Known contraindication for tSCS (pacemakers or other implantable stimulators); * Prior exposure to tSCS treatment; * Inability to provide informed consent. Caregiver: • Inability to provide informed consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Singapore General Hospital Singapore Singapore

More Singapore General Hospital trials in Singapore

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07438353 on ClinicalTrials.gov ↗ ← All trials in Singapore